-
公开(公告)号：US08653071B2
公开(公告)日：2014-02-18
申请号：US13519298
申请日：2010-05-03
申请人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Kana Ram Kumawat , Ishtiyaque Ahmad , Pradeep Jayarajan , Anil Karbhari Shinde , Nagaraj Vishwottam Kandikere , Koteshwara Mudigonda , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Kana Ram Kumawat , Ishtiyaque Ahmad , Pradeep Jayarajan , Anil Karbhari Shinde , Nagaraj Vishwottam Kandikere , Koteshwara Mudigonda , Venkateswarlu Jasti
IPC分类号： A61K31/5377 , A61K31/497 , A61K31/496 , A61K31/4709 , A61K31/4427 , A61K31/404 , A61K31/403 , C07D413/14 , C07D401/02 , C07D401/14 , C07D215/00 , C07D209/04 , C07D209/02
CPC分类号： C07D401/14 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06
摘要： The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.
摘要翻译： 本发明涉及式（I）的新型α4beta2神经元烟碱乙酰胆碱受体配体化合物及其衍生物，立体异构体，药学上可接受的盐和含有它们的组合物。 本发明涉及式（I）的新型α4beta2神经元烟碱乙酰胆碱受体配体化合物及其衍生物，立体异构体，药学上可接受的盐和含有它们的组合物。
-
公开(公告)号：US20120129816A1
公开(公告)日：2012-05-24
申请号：US13063436
申请日：2009-03-03
申请人： Ramakrishna Nirogi , Anil Karbhari Shinde , Rama Sastri Kambhampati , Pradeep Jayarajan , Gopinadh Bhyrapuneni , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Anil Karbhari Shinde , Rama Sastri Kambhampati , Pradeep Jayarajan , Gopinadh Bhyrapuneni , Venkateswarlu Jasti
IPC分类号： A61K31/4468 , A61P25/28 , A61P25/24 , A61P25/16 , A61P25/08 , A61P25/06 , A61P25/00 , A61P25/18 , A61P25/30 , A61P1/00 , A61P3/04 , A61K31/46 , A61K31/55 , A61K31/473 , A61K31/496 , A61K31/65 , C07D211/58
CPC分类号： C07D295/30 , C07D333/62
摘要： The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.
摘要翻译： 本发明涉及式（I）的新型芳基磺酰胺胺，其互变异构形式，其立体异构体，其多晶型物，其药学上可接受的盐，本文所述的其药学上可接受的溶剂合物和含有它们的药学上可接受的组合物。
-
公开(公告)号：US09079888B2
公开(公告)日：2015-07-14
申请号：US14000362
申请日：2011-06-07
申请人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Amol Dinakar Deshpande , Adi Reddy Dwarampudi , Narasimhareddy Gangadasari , Sangram Keshari Saraf , Vishwottam Nagaraj Kandikere , Pradeep Jayarajan , Ishtiyaque Ahmad , Mohmadsadik Abdulhamid Mulla , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Amol Dinakar Deshpande , Adi Reddy Dwarampudi , Narasimhareddy Gangadasari , Sangram Keshari Saraf , Vishwottam Nagaraj Kandikere , Pradeep Jayarajan , Ishtiyaque Ahmad , Mohmadsadik Abdulhamid Mulla , Venkateswarlu Jasti
IPC分类号： C07D401/12 , C07D405/12 , C07D413/12 , C07D401/14 , C07D211/46
CPC分类号： C07D401/14 , C07D211/46 , C07D401/12 , C07D405/12 , C07D413/12
摘要： The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above compounds of formula (I), and their pharmaceutically acceptable salts.The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors.
摘要翻译： 本发明涉及式（I）的新化合物及其药学上可接受的盐和组合物。 本发明还涉及制备上述式（I）化合物及其药学上可接受的盐的方法。 式（I）化合物可用于治疗与组胺H3受体相关的各种疾病。
-
公开(公告)号：US20140135304A1
公开(公告)日：2014-05-15
申请号：US14000362
申请日：2011-06-07
申请人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Amol Dinakar Deshpande , Adi Reddy Dwarampudi , Narasimhareddy Gangadasari , Sangram Keshari Saraf , Vishwottam Nagaraj Kandikere , Pradeep Jayarajan , Ishtiyaque Ahmad , Mohmadsadik Abdulhamid Mulla , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Amol Dinakar Deshpande , Adi Reddy Dwarampudi , Narasimhareddy Gangadasari , Sangram Keshari Saraf , Vishwottam Nagaraj Kandikere , Pradeep Jayarajan , Ishtiyaque Ahmad , Mohmadsadik Abdulhamid Mulla , Venkateswarlu Jasti
IPC分类号： C07D401/14 , C07D401/12 , C07D211/46
CPC分类号： C07D401/14 , C07D211/46 , C07D401/12 , C07D405/12 , C07D413/12
摘要： The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts.The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors.
摘要翻译： 本发明涉及式（I）的新化合物及其药学上可接受的盐和组合物。 本发明还涉及制备上述新化合物及其药学上可接受的盐的方法。 式（I）化合物可用于治疗与组胺H3受体相关的各种疾病。
-
公开(公告)号：US09079894B2
公开(公告)日：2015-07-14
申请号：US13982486
申请日：2012-01-05
申请人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Suresh Yarlagadda , Srinivasa Rao Ravella , Anil Karbhari Shinde , Ramasastri Kambhampati , Praveen Kumar Roayapalley , Pradeep Jayarajan , Gopinadh Bhyrapuneni , Sriramachandra Murthy Patnala , Jyothsna Ravula , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Suresh Yarlagadda , Srinivasa Rao Ravella , Anil Karbhari Shinde , Ramasastri Kambhampati , Praveen Kumar Roayapalley , Pradeep Jayarajan , Gopinadh Bhyrapuneni , Sriramachandra Murthy Patnala , Jyothsna Ravula , Venkateswarlu Jasti
IPC分类号： A61K31/445 , C07D401/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00 , C07D421/00 , C07D211/22 , C07D211/32 , C07D413/14 , C07D413/06
CPC分类号： A61K31/454 , A61K31/4245 , C07D413/06 , C07D413/14
摘要： The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.
摘要翻译： 本发明涉及式（I）的新化合物及其药学上可接受的盐和组合物。 本发明还涉及制备上述新化合物及其药学上可接受的盐的方法。 式（I）化合物可用于治疗与5-HT4受体相关的各种疾病。
-
公开(公告)号：US20140148440A1
公开(公告)日：2014-05-29
申请号：US13818152
申请日：2010-11-15
申请人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Rambabu Namala , Adi Reddy Dwarampudi , Laxman Kota , Murlimohan Gampa , Padmavathi Kodru , Taraka Naga Vinaykumar Tiriveedhi , Vishwottam Nagaraj Kandikere , Nageshwara Rao Muddana , Ramanatha Shrikantha Saralaya , Pradeep Jayarajan , Dhanalakshmi Shanmuganathan , Ishtiyaque Ahmad , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Rambabu Namala , Adi Reddy Dwarampudi , Laxman Kota , Murlimohan Gampa , Padmavathi Kodru , Taraka Naga Vinaykumar Tiriveedhi , Vishwottam Nagaraj Kandikere , Nageshwara Rao Muddana , Ramanatha Shrikantha Saralaya , Pradeep Jayarajan , Dhanalakshmi Shanmuganathan , Ishtiyaque Ahmad , Venkateswarlu Jasti
IPC分类号： C07D513/04 , C07D417/12
CPC分类号： C07D513/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04
摘要： The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors, for example cognitive disorders, sleep disorders, obesity and pain.
摘要翻译： 本发明涉及式（I）的杂环基化合物及其药学上可接受的盐和组合物。 本发明还涉及制备上述新化合物及其药学上可接受的盐的方法。 式（I）化合物可用于治疗与组胺H3受体相关的各种疾病，例如认知障碍，睡眠障碍，肥胖症和疼痛。
-
公开(公告)号：US08912179B2
公开(公告)日：2014-12-16
申请号：US13818152
申请日：2010-11-15
申请人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Rambabu Namala , Adi Reddy Dwarampudi , Laxman Kota , Murlimohan Gampa , Padmavathi Kodru , Taraka Naga Vinaykumar Tiriveedhi , Vishwottam Nagaraj Kandikere , Nageshwara Rao Muddana , Ramanatha Shrikantha Saralaya , Pradeep Jayarajan , Dhanalakshmi Shanmuganathan , Ishtiyaque Ahmad , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Anil Karbhari Shinde , Ramasastri Kambhampati , Rambabu Namala , Adi Reddy Dwarampudi , Laxman Kota , Murlimohan Gampa , Padmavathi Kodru , Taraka Naga Vinaykumar Tiriveedhi , Vishwottam Nagaraj Kandikere , Nageshwara Rao Muddana , Ramanatha Shrikantha Saralaya , Pradeep Jayarajan , Dhanalakshmi Shanmuganathan , Ishtiyaque Ahmad , Venkateswarlu Jasti
IPC分类号： A61K31/535 , A61K31/55 , C07D513/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04
CPC分类号： C07D513/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04
摘要： The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors, for example cognitive disorders, sleep disorders, obesity and pain.
摘要翻译： 本发明涉及式（I）的杂环基化合物及其药学上可接受的盐和组合物。 本发明还涉及制备上述新化合物及其药学上可接受的盐的方法。 式（I）化合物可用于治疗与组胺H3受体相关的各种疾病，例如认知障碍，睡眠障碍，肥胖症和疼痛。
-
8.发明授权公开(公告)号：US08598204B2
公开(公告)日：2013-12-03
申请号：US13393539
申请日：2009-12-29
申请人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Ishtiyaque Ahmad , Pradeep Jayarajan , Nagaraj Vishwottam Kandikere , Anil Karbhari Shinde , Rama Sastri Kambhampati , Gopinadh Bhyrapuneni , Jyothsna Ravula , Sriramachandra Murthy Patnala , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Ishtiyaque Ahmad , Pradeep Jayarajan , Nagaraj Vishwottam Kandikere , Anil Karbhari Shinde , Rama Sastri Kambhampati , Gopinadh Bhyrapuneni , Jyothsna Ravula , Sriramachandra Murthy Patnala , Venkateswarlu Jasti
IPC分类号： A61K31/04 , C07D215/38
CPC分类号： C07D401/12 , C07D471/10 , C07D471/12
摘要： The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.
摘要翻译： 本发明涉及新的式（I）的1,2-二氢-2-氧代喹啉化合物及其衍生物，前体药物，互变异构体，立体异构体，多晶型物，溶剂化物，水合物，代谢物，N-氧化物，药学上可接受的盐和组合物 包含它们 本发明还涉及制备上述新化合物及其衍生物，前体药物，互变异构体，立体异构体，多晶型物，溶剂合物，水合物，代谢物，N-氧化物，药学上可接受的盐和含有它们的组合物的方法。 本发明的化合物可用于治疗/预防由5-HT4受体活性介导的各种疾病。
-
公开(公告)号：US20120322808A1
公开(公告)日：2012-12-20
申请号：US13519298
申请日：2010-05-03
申请人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Kana Ram Kumawat , Ishtiyaque Ahmad , Pradeep Jayarajan , Anil Karbhari Shinde , Nagaraj Vishwottam Kandikere , Koteshwara Mudigonda , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Kana Ram Kumawat , Ishtiyaque Ahmad , Pradeep Jayarajan , Anil Karbhari Shinde , Nagaraj Vishwottam Kandikere , Koteshwara Mudigonda , Venkateswarlu Jasti
IPC分类号： A61K31/403 , A61K31/4439 , A61P25/22 , A61P25/28 , A61P25/24 , A61P25/00 , A61P25/08 , A61P3/04 , A61P25/04 , C07D209/52 , C07D405/04 , C07D401/14 , A61K31/496 , A61K31/497 , C07D403/04 , A61K31/506 , C07D401/04 , A61K31/4709 , C07D401/06
CPC分类号： C07D401/14 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06
摘要： The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.
摘要翻译： 本发明涉及式（I）的新型α4和bgr2神经元烟碱乙酰胆碱受体配体化合物及其衍生物，立体异构体，药学上可接受的盐和含有它们的组合物。 本发明涉及式（I）的新型α4和bgr2神经元烟碱乙酰胆碱受体配体化合物及其衍生物，立体异构体，药学上可接受的盐和含有它们的组合物。
-
10.发明授权公开(公告)号：US08735423B2
公开(公告)日：2014-05-27
申请号：US13499998
申请日：2009-12-31
申请人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Srinivas Veeramalla , Srinivasa Rao Ravella , Ishtiyaque Ahmad , Pradeep Jayarajan , Anil Karbhari Shinde , Rama Sastri Kambhampti , Gopinadh Bhyrapuneni , Venkateswarlu Jasti
发明人： Ramakrishna Nirogi , Abdul Rasheed Mohammed , Srinivas Veeramalla , Srinivasa Rao Ravella , Ishtiyaque Ahmad , Pradeep Jayarajan , Anil Karbhari Shinde , Rama Sastri Kambhampti , Gopinadh Bhyrapuneni , Venkateswarlu Jasti
IPC分类号： C07D401/12 , A61K31/403
CPC分类号： C07D401/12
摘要： The present invention relates to novel bicyclic compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment and prevention of various disorders that are related to α4β2 nicotinic receptors.
摘要翻译： 本发明涉及式（I）的新型双环化合物及其衍生物，前体药物，互变异构体，立体异构体，多晶型物，溶剂合物，水合物，代谢物，N-氧化物，药学上可接受的盐和含有它们的组合物。 本发明还涉及制备上述新化合物及其衍生物，前体药物，互变异构体，立体异构体，多晶型物，溶剂合物，水合物，代谢物，N-氧化物，药学上可接受的盐和含有它们的组合物的方法。 这些化合物可用于治疗和预防与α4和bgr2烟碱受体相关的各种疾病。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.015 秒)
